2015-31042. New Animal Drugs; Approval of New Animal Drug Applications; Withdrawals of Approval of New Animal Drug Applications; Changes of Sponsorship  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule; technical amendments.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect application-related actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during September and October 2015. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect changes of sponsorship of applications and the voluntary withdrawals of approval of applications that occurred in September and October 2015.

    DATES:

    This rule is effective December 9, 2015, except for the amendments to 21 CFR 520.446, 520.2043, 558.625, and 558.630, which are effective December 21, 2015.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    George K. Haibel, Center for Veterinary Medicine (HFV-6), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5689, george.haibel@fda.hhs.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Start Printed Page 76385

    I. Approval Actions

    FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during September and October 2015, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the Center for Veterinary Medicine FOIA Electronic Reading Room: http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm. Marketing exclusivity and patent information may be accessed in FDA's publication, Approved Animal Drug Products Online (Green Book) at: http://www.fda.gov/​AnimalVeterinary/​Products/​ApprovedAnimalDrugProducts/​default.htm.

    Table 1—Original and Supplemental NADAs and ANADAs Approved During September and October 2015

    File No.SponsorProduct nameAction21 CFR sectionFOIA summaryNEPA review
    141-440Piedmont Animal Health, 204 Muirs Chapel Rd., suite 200, Greensboro, NC 27410CLARO (florfenicol, terbinafine, mometasone furoate) Otic SolutionOriginal approval for the treatment of otitis externa in dogs524.957yesCE.1 2
    141-449Intervet, Inc., 2 Giralda Farms, Madison, NJ 07940SAFE-GUARD AquaSol (fenbendazole oral suspension) Suspension ConcentrateOriginal approval for the treatment and control of certain nematode worms in broiler chickens, replacement chickens intended to become breeding chickens, and breeding chickens520.905ayesEA/ FONSI.3
    141-442Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007LUTALYSE HighCon (dinoprost tromethamine injection) InjectionSupplemental approval of subcutaneous route of administration522.690yesCE.1 4
    108-901Zoetis Inc. 333 Portage St., Kalamazoo, MI 49007LUTALYSE (dinoprost tromethamine injection) InjectionSupplemental approval of revised indications for uses in cattle522.690noCE.1 4
    1 The Agency has determined that this action is categorically excluded (CE) from the requirement to submit an environmental assessment or an environmental impact statement because it is of a type that does not have a significant effect on the human environment.
    2 CE granted under 21 CFR 25.33(d)(1).
    3 The Agency has carefully considered an environmental assessment (EA) of the potential environmental impact of this action and has made a finding of no significant impact (FONSI).
    4 CE granted under 21 CFR 25.33(a)(1).

    II. Changes of Sponsorship

    During September and October 2015, ownership of, and all rights and interest in, the following approved applications have been transferred as follows:

    File No.Previous sponsorProduct nameNew sponsor21 CFR section
    141-440Piedmont Animal Health, 204 Muirs Chapel Rd., suite 200, Greensboro, NC 27410CLARO (florfenicol, terbinafine, mometasone furoate) Otic SolutionBayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201524.957
    200-582Orkeo USA, Inc., 77 Water St., New York, NY 10005LONCOR 300 (florfenicol) Injectable SolutionBayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201522.955

    As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these changes of sponsorship. Following the change of sponsorship of ANADA 200-582, Orkeo USA, Inc., is no longer the sponsor of an approved application.

    III. Withdrawals of Approval

    In addition, during September and October 2015, the following three sponsors have requested that FDA withdraw approval of the NADAs and ANADAs listed in the following table because the products are no longer manufactured or marketed:

    File No.SponsorProduct name21 CFR section
    140-680 1Pharmgate LLC, 1015 Ashes Dr., suite 102, Wilmington, NC 28405TYLAN (tylosin phosphate) Premix558.625
    Start Printed Page 76386
    140-681 1Pharmgate LLC, 1015 Ashes Dr., suite 102, Wilmington, NC 28405TYLAN SULFA G (tylosin phosphate and sulfamethazine) Premix558.630
    200-028Pegasus Laboratories, Inc., 8809 Ely Rd., Pensacola, FL 32514EVICT 300 (pyrantel pamoate) Suspension520.2043
    200-383Bayer HealthCare LLC, Animal Health Division, P.O. Box 390, Shawnee Mission, KS 66201CLINDAROBE (clindamycin) Capsules520.446
    1 These NADAs were identified as being affected by guidance for industry #213, “New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,” December 2013.

    Elsewhere in this issue of the Federal Register, FDA gave notice that approval of NADA 140-680, NADA 140-681, ANADA 200-028, and ANADA 200-383, and all supplements and amendments thereto, is withdrawn, effective December 21, 2015. As provided in the regulatory text of this document, the animal drug regulations are amended to reflect these voluntary withdrawals of approval.

    IV. Technical Amendments

    FDA has noticed that a previous sponsor of ANADA 200-383, Teva Canada Ltd., was no longer the sponsor of an approved application following a prior change of sponsorship. At this time, FDA is amending the regulation to remove the firm from the listings of sponsors of approved applications in 21 CFR 510.600. This action is being taken to improve the accuracy of the regulations.

    FDA is also revising the special considerations for medicated feeds containing veterinary feed directive drugs to align with 21 CFR 558.6(a)(6), which was recently amended (80 FR 31708, June 3, 2015). This action is being taken to improve the consistency of the regulations.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability”. Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects

    21 CFR Part 510

    • Administrative practice and procedure
    • Animal drugs
    • Labeling
    • Reporting and recordkeeping requirements

    21 CFR Parts 520, 522, and 524

    • Animal drugs

    21 CFR Part 558

    • Animal drugs
    • Animal feeds
    End List of Subjects

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 524, and 558 are amended as follows:

    Start Part

    PART 510—NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 510 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

    End Authority
    [Amended]
    Start Amendment Part

    2. In § 510.600:

    End Amendment Part Start Amendment Part

    a. In the table in paragraph (c)(1), remove the entries for “Orkeo USA, Inc.” and “Teva Canada Ltd.”; and

    End Amendment Part Start Amendment Part

    b. In the table in paragraph (c)(2), remove the entries for “043806” and “086050”.

    End Amendment Part Start Part

    PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    3. The authority citation for 21 CFR part 520 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority
    [Amended]
    Start Amendment Part

    4. Effective December 21, 2015, in § 520.446, in paragraph (b)(1), remove “Nos. 000859 and 054771” and in its place add “No. 054771”.

    End Amendment Part Start Amendment Part

    5. In § 520.905a:

    End Amendment Part Start Amendment Part

    a. Revise paragraphs (a) and (e)(4)(i);

    End Amendment Part Start Amendment Part

    b. In paragraph (e)(4)(iii), remove the first sentence; and

    End Amendment Part Start Amendment Part

    c. Add paragraph (e)(5).

    End Amendment Part

    The revisions and addition read as follows:

    Fenbendazole suspension.

    (a) Specifications. Each milliliter of suspension contains 100 milligrams (mg) fenbendazole for use as in paragraphs (e)(1), (2), (3), and (4) of this section; or 200 mg fenbendazole for use as in paragraph (e)(5) of this section.

    * * * * *

    (e) * * *

    (4) * * *

    (i) Amount. Administer orally 5 mg/kg of body weight (2.3 mg/lb). Retreatment may be needed after 4 to 6 weeks.

    * * * * *

    (5) Chickens—(i) Amount. Administer orally via drinking water at a daily dose of 1 mg/kg body weight (0.454 mg/lb) for 5 consecutive days.

    (ii) Indications for use. For the treatment and control of adult Ascaridia galli in broiler chickens and replacement chickens intended to become breeding chickens, and for the treatment and control of adult A. galli and Heterakis gallinarum in breeding chickens.

    (iii) Limitations. Not for use in laying hens and replacement chickens intended to become laying hens.

    [Amended]
    Start Amendment Part

    6. Effective December 21, 2015, in § 520.2043, in paragraph (b)(2), remove “Nos. 054771, 055246, 058829, and 059130” and in its place add “Nos. 000859, 054771, and 058829”.

    End Amendment Part Start Part

    PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    7. The authority citation for 21 CFR part 522 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority Start Amendment Part

    8. In § 522.690, revise paragraphs (b)(2) and (d)(1)(i) and add paragraph (b)(3) to read as follows:

    End Amendment Part
    Dinoprost.
    * * * * *

    (b) * * *

    (2) No. 054771 for use of the 5 mg/mL product as in paragraphs (d)(1), (2), and (3) of this section.

    (3) No. 000859 for use of the 5 mg/mL product as in paragraphs (d)(2), (3), and (4) of this section.

    * * * * *

    (d) * * *

    (1) * * *

    (i) Amount. 25 mg as a single intramuscular or subcutaneous injection.

    * * * * *
    [Amended]
    Start Amendment Part

    9. In § 522.955(b)(2), remove “086050” and in its place add “000859”.

    End Amendment Part Start Part Start Printed Page 76387

    PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    10. The authority citation for 21 CFR part 524 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority Start Amendment Part

    11. Add § 524.957 to read as follows:

    End Amendment Part
    Florfenicol, terbinafine, and mometasone otic solution.

    (a) Specifications. Each single-dose, prefilled dropperette contains 1 milliliter (mL) of a solution containing 15 milligrams (mg) florfenicol, 13.3 mg terbinafine, and 2 mg mometasone furoate.

    (b) Sponsor. See No. 000859 in § 510.600(c) of this chapter.

    (c) Conditions of use in dogs—(1) Amount. Administer one dropperette (1 mL) per affected ear(s).

    (2) Indications for use. For the treatment of otitis externa in dogs associated with susceptible strains of yeast (Malassezia pachydermatis) and bacteria (Staphylococcus pseudintermedius).

    (3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

    Start Part

    PART 558—NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS

    End Part Start Amendment Part

    12. The authority citation for 21 CFR part 558 continues to read as follows:

    End Amendment Part Start Authority

    Authority: (P>21 U.S.C. 354, 360b, 360ccc, 360ccc-1, 371.

    End Authority Start Amendment Part

    13. In § 558.68, revise paragraph (c)(1) to read as follows:

    End Amendment Part
    Avilamycin.
    * * * * *

    (c) * * *

    (1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See § 558.6 for additional requirements.

    * * * * *
    Start Amendment Part

    14. In § 558.261, revise paragraphs (c)(1) and (2) introductory text to read as follows:

    End Amendment Part
    Florfenicol.
    * * * * *

    (c) * * *

    (1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See § 558.6 for additional requirements.

    (2) The expiration date of VFDs for florfenicol medicated feeds:

    * * * * *
    Start Amendment Part

    15. In § 558.618, revise paragraph (c)(1) to read as follows:

    End Amendment Part
    Tilmicosin.
    * * * * *

    (c) * * *

    (1) Federal law restricts medicated feed containing this veterinary feed directive (VFD) drug to use by or on the order of a licensed veterinarian. See § 558.6 for additional requirements.

    * * * * *
    [Amended]
    Start Amendment Part

    16. Effective December 21, 2015, in § 558.625, remove paragraph (b)(5) and redesignate paragraph (b)(6) as paragraph (b)(5).

    End Amendment Part
    [Amended]
    Start Amendment Part

    17. Effective December 21, 2015, in § 558.630, in paragraph (b)(2), remove “Nos. 054771 and 069254” and in its place add “No. 054771”.

    End Amendment Part Start Signature

    Dated: December 4, 2015.

    Bernadette Dunham,

    Director, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. 2015-31042 Filed 12-8-15; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Effective Date:
12/9/2015
Published:
12/09/2015
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule; technical amendments.
Document Number:
2015-31042
Dates:
This rule is effective December 9, 2015, except for the amendments to 21 CFR 520.446, 520.2043, 558.625, and 558.630, which are effective December 21, 2015.
Pages:
76384-76387 (4 pages)
Docket Numbers:
Docket No. FDA-2015-N-0002
Topics:
Administrative practice and procedure, Animal drugs, Animal feeds, Labeling, Reporting and recordkeeping requirements
PDF File:
2015-31042.pdf
Supporting Documents:
» FONSI for sN 141-361, approved December 7, 2015
» FONSI for oN 141-453, approved December 8, 2015
» FOI Summary for sN 141-361, approved December 7, 2015
» FOI Summary for sN 141-258, approved December 2, 2015
» FOI Summary for oN 141-453, approved December 8, 2015
» EA for sN 141-361, approved December 7, 2015
» EA for oN 141-453, approved December 8, 2015
» Finding of No Significant Impact (FONSI) for SAFE-GUARD AQUASOL (fenbendazole oral suspension) in Chickens
» FREEDOM OF INFORMATION SUMMARY NADA 141-442 LUTALYSE HighCon Injection Dinoprost Tromethamine Injection Lactating dairy cows, beef cows, beef heifers, and replacement dairy heifers
» FREEDOM OF INFORMATION SUMMARY NADA 141-449 SAFE-GUARD AquaSol Fenbendazole oral suspension Broiler chickens, replacement chickens intended to become breeding chickens, and breeding chickens
CFR: (12)
21 CFR 510.600
21 CFR 520.446
21 CFR 520.2043
21 CFR 522.690
21 CFR 522.955
More ...